# Tucuvi **Source:** https://geo.sig.ai/brands/tucuvi **Vertical:** Healthcare Tech **Subcategory:** Clinical Voice AI **Tier:** Emerging **Website:** tucuvi.com **Last Updated:** 2026-04-14 ## Summary Tucuvi's LOLA is the first EU Class IIb certified AI medical voice agent; in 60+ health systems with $20M Series A, running post-discharge follow-ups and chronic care check-ins (Jan 2026). ## Company Overview Tucuvi is a Spanish clinical AI company that has developed LOLA, a conversational voice AI agent for healthcare. LOLA conducts automated clinical conversations with patients — including post-discharge follow-ups, chronic disease monitoring check-ins, pre-appointment screenings, and medication adherence calls — with the tone, clinical accuracy, and empathy expected of a skilled nurse or care coordinator. Tucuvi was founded by a team combining clinical expertise and AI engineering to address the growing gap between care demand and available clinical staff in European health systems.\n\nThe LOLA platform integrates with hospital information systems and electronic health records, enabling health systems to deploy automated voice interactions at scale across their patient populations. The system is multilingual and capable of conducting clinically meaningful conversations that capture structured data, flag deteriorating patients, and escalate to human clinicians when needed. Unlike general-purpose voice assistants, LOLA is specifically trained on clinical language, patient interaction patterns, and healthcare workflows.\n\nTucuvi achieved a landmark regulatory milestone by becoming the first EU Class IIb certified AI medical device in the voice AI category, a certification level that covers devices posing moderate to high risk — the same classification as many implantable devices. This certification is a significant commercial differentiator in Europe's tightly regulated healthcare market. The company raised a $20M Series A, serves 60+ health systems, and has conducted 300,000+ clinical voice calls. Its 2025–2026 momentum reflects growing European health system interest in AI that can extend care capacity without adding nursing headcount. ## Frequently Asked Questions ### What is LOLA? LOLA is Tucuvi's AI voice agent that conducts clinical conversations with patients — handling post-discharge follow-ups, chronic disease check-ins, medication adherence monitoring, and pre-appointment screenings. It is designed to replicate the quality of a nurse-led call while operating at a scale that human staff cannot match, and it escalates to clinicians when it detects patient deterioration. ### What does EU Class IIb certification mean for Tucuvi? EU Class IIb is a medical device certification covering moderate-to-high-risk devices, the same regulatory class as many surgical instruments and active implants. Tucuvi is the first voice AI to achieve this certification in Europe, which gives it a significant compliance advantage when selling into regulated health system procurement processes that require certified medical devices. ### Who uses Tucuvi? Tucuvi serves 60+ health systems, primarily in Europe. Its customers are hospitals and integrated care organizations that need to increase patient contact rates for chronic disease management and post-acute follow-up without expanding nursing headcount — a priority for health systems facing staffing shortages and rising patient volumes. ### What types of clinical conversations does LOLA conduct? LOLA conducts post-discharge follow-up calls within 24-48 hours of hospital discharge (the highest-risk period for readmission), chronic disease management check-ins for conditions like diabetes, COPD, and heart failure, medication adherence monitoring calls, and pre-appointment symptom screenings. Each conversation follows validated clinical protocols and uses natural language understanding to interpret patient responses, escalating to a human nurse or physician when concerning symptoms or safety issues are detected. ### What languages does LOLA support and in what countries is Tucuvi deployed? LOLA supports multiple languages with a primary focus on Spanish and European languages, reflecting Tucuvi's European health system deployment base (60+ health systems primarily in Europe). Tucuvi's technology is designed for multilingual deployment as it expands — clinical voice AI must support the language of patients for both accuracy and patient comfort, making multilingual capability a core technical requirement for international health system sales. ### How does EU Class IIb certification affect Tucuvi's competitive position? EU Class IIb medical device certification is a significant regulatory barrier — it requires extensive clinical evidence, quality management systems, and regulatory review by a notified body. Most voice AI companies have not achieved this certification, making Tucuvi's certified status a competitive moat in European regulated health system procurement. Public health systems in Europe that must comply with EU medical device regulations can only deploy certified tools, which excludes most AI voice competitors from Tucuvi's market. ### What is the clinical evidence behind Tucuvi's LOLA reducing hospital readmissions? Tucuvi's health system deployments have generated data showing that LOLA-powered post-discharge follow-up reduces 30-day readmission rates for chronic disease patients — the primary outcome metric for value-based care programs in Europe and the US. Consistent monitoring that human staff cannot provide at scale catches deterioration earlier. Tucuvi publishes clinical outcomes data from its 60+ health system deployments to support evidence-based procurement decisions. ### How is Tucuvi funded and what is its growth trajectory? Tucuvi is a Spanish-founded healthtech company backed by European venture capital. The company has raised multi-million euro rounds supporting commercial expansion across European health systems. Revenue comes from subscription contracts with health systems — typically multi-year agreements covering defined patient populations. Tucuvi's 60+ health system customer base and EU Class IIb regulatory status position it as the leading clinical voice AI platform in Europe with a natural expansion path to US markets. ## Tags b2b, healthtech, saas --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*